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Introduction 
The most common malignancy in the human person is skin cancer and the incidence is 
increasing [33]. Skin cancer can be considered as melanoma or non melanoma skin cancer 
(NMSC) the latter being usually basal cell (BCC) or cutaneous squamous cell carcinoma 
(cSCC). Australia has the highest incidence of skin cancer in the world, at nearly four times 
the rates in Canada, the USA and the UK. The incidence of skin cancer is five times that of 
any other cancer in the country [34]. On an annual basis, over 10 600 Australians will develop 
a melanoma [2].  
 
Furthermore, the incidence of skin cancer in Australia is rising. From 1985 to 2002,   
age-standardized incidence rates of BCC and SCC had increased by 35% and 133% 
respectively [34]. The mortality is also increasing. From 1984 to 2005, the number of deaths 
in Australia per year increased for melanoma from 640 to 1 273; and for NMSC from 228  
to 405 [1].  
 
Skin cancer is also the most expensive Australian cancer. Most Australian Government 
funding allocated to cancer care is spent on skin cancer. In 2001, it was estimated the 
treatment of non-melanoma skin cancer cost $264 million and melanoma $30 million [4]. 
Most skin cancers are treated at an early stage with therapies such as surgery, cytotoxic or 
immunogenic skin lotions. Radiation is also an effective treatment modality in many 
scenarios of the treatment of skin cancer [29]. 
 
The therapeutic ratio  
A fundamental concept in cancer management is the therapeutic ratio [28]. The therapeutic 
ratio is that ratio of tumour cure to normal tissue toxicity. The aim of all cancer therapy is to 
maximize the therapeutic ratio, that is, to achieve maximal tumour cell kill for the minimum 
of normal tissue toxicity. It guides all cancer disciplines. The therapeutic ratio offers a way of 
assessing the relative merits of new technologies particularly in terms of a holistic approach to 
patient management.    INT. J. BIOAUTOMATION, 2012, 16(1), 43-52 
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The ideal therapeutic ratio ensures durable tumour control and a high quality of life post 
treatment. A technique that develops a better cure rate may not be embraced because it 
delivers significant normal tissue toxicity. Another that produces equivalent cure rates may 
become standard treatment because of its better normal tissue side effect profile. Often the 
concept of maximizing the therapeutic ratio is expressed more simply as improving patient 
outcomes. Hence the statement that a new technology is embraced as it delivers a better 
outcome. 
 
There are particular ways in which radiation techniques can lead to a better therapeutic ratio. 
One is by the ability radiation has to selectively kill tumour cells and preserve normal cells 
within an irradiated volume when appropriately delivered. The paradigm situation is breast 
conservation, now the most common reason for prescribing radiation on a world scale [27]. 
Tissue conservation plays a role in other tumor types such as head and neck (larynx 
preservation) [25], SCC anus (sphincter preservation) [30] and also skin cancer, with 
preservation of normal skin within the treatment volume [24]. Oftentimes this is why 
radiation is selected instead of surgery for definitive treatment or is used as adjuvant to more 
limited surgery with less tissue being sacrificed. 
 
The second way in which radiation can augment the therapeutic ratio has been the increasing 
conformality of radiation dose to the volume requiring treatment. Radiotherapy treatment 
modalities are becoming more and more conformal as better technologies evolve [32].   
This allows for improved conformality of radiation dose to the volume at risk of disease yet 
sparing the unnecessary irradiation of normal tissue so reducing toxicity [7]. This is not 
always easy as external beam radiotherapy often needs to enter and exit the body through 
normal tissues in order to cover tissue at risk of tumour.  
 
Methodologies 
The various types of projects, on which the research in this paper is based, and the associated 
methodologies are listed in the Table 1. The row headings are the numbers in the reference list 
at the end of this paper. Other ways of reaching clinical decisions may be found in [6, 30,  
32, 35]. 
 
New technologies 
New technologies can play a significant role in decreasing skin cancer related mortality, 
morbidity and cost. New technologies can be considered by whether they involve molecular, 
clinical, imaging or therapeutic advances. Molecular advances are examined in a laboratory 
setting and include technologies that bring new understanding to how things work at a 
fundamental biochemical level.  
 
The new technologies are new discoveries or new ways of integrating current technology that 
impact on the outcomes of skin cancer patients. As Australia has the highest incidence of skin 
cancer in the world, spends the majority of its cancer budget on skin cancer and has rising 
incidence and mortality from this group of diseases, it is only fitting that Australia plays a 
leading role in the development of these new technologies. The rate of discovery and 
utilization of new technologies in radiotherapy are accelerating [3, 26, 31]. 
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Table 1. 
Ref  Randomized 
trial 
Laboratory 
study 
Retrospective 
series  Audit Case study  Planning
8        ×   
9       ×    
10     ×      
11       ×    
12   ×       
13         ×   
14           × 
15     ×      
16     ×      
17     ×      
18           × 
19     ×      
20           × 
21     ×     × 
22   ×       
23   ×       
24  ×          
 
Molecular analyses (see section (a) below) investigate the most foundational mechanisms in 
cancer research. When these technologies have an impact on clinical management they can be 
considered as translational. A translational project is one where there is a laboratory and 
clinical interaction that leads to better patient outcomes [5]. Advances in radiation techniques 
are essential to maximizing the therapeutic ratio (see section (b)). Clinical advances (see   
section (c)) are new technologies that impact on actual clinical practice; that is, what actually 
happens at the bed side. Clinical Imaging advances cover new ways of using investigations 
that evaluate tumour or normal tissues to guide therapy. Treatment advances describe how 
these new technologies specifically affect an outcome. Timing of clinical interventions 
especially in the multidisciplinary era is important for disease control. These divisions can 
seem artificial; all worthwhile new technologies should lead to a specific advance in the 
therapeutic ratio. However, it is a useful division to enable comparison of current versus new 
and better modalities.  
 
Some related research results 
(a)   The molecular analyses were all translational projects. The first concentrated on 
cutaneous squamous cell carcinoma. The Peter MacCallum Cancer Centre (PMCC) in 
Melbourne, Victoria, Australia, is a tertiary referral centre for locally advanced cutaneous 
squamous cell carcinoma (cSCC) from that State. This study was the characterization of the 
epidermal growth factor receptor (EGFR) in cSCC. EGFR is up regulated in many cancers. 
Epidermal growth factor receptor inhibitor drugs (EGFRI) were being trialed at that time in   INT. J. BIOAUTOMATION, 2012, 16(1), 43-52 
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mucosal, that is, non-cutaneous squamous cell carcinoma (SCC) of head and neck in 
combination with radiotherapy. For the study [22] we used a quantitative western block 
technique called the LiCor system that was new to our laboratory. We compared these results 
to immunohistochemistry and clinical outcomes. This study found, counter to intuition, that 
EGFR was present and activated only in a minority of cSCC evaluated. EGFR was not related 
to activation of downstream events or clinical outcomes. This paper lead to recognition in our 
institution that it is necessary to confirm the existence of the target in the cells requiring 
treatment before embarking on a full study of a targeted cancer agent. 
 
The second project [23] was based on anecdotal evidence that fair skinned patients have more 
severe radiotherapy reactions. Single nucleotide polymorphisms (SNPs) of the melanocortin-
1-receptor gene (MC1R) had already been found to be the main driver of skin colour. The 
project investigated the relationship of SNPs of MC1R and their relationship with 
unexpectedly severe radiation reactions. The MC1R genotype of a cohort of Australians with 
unexpectedly severe acute and/or late skin reactions from radiotherapy for cancer (n = 30) 
was analyzed. The findings were compared to control data from a previous study of MC1R 
representative of the general Australian population (n = 1787). The difference in frequency of 
alleles encoding a “Red Hair Colour” (RHC) phenotype in the cohort of patients with 
unexpectedly severe acute skin radiation reactions (n = 12) was significantly increased 
compared to the control population (p = 0.003). Acute radiosensitivity was especially 
associated with the R160W variant allele [odds ratio = 3.64 (95% CI = 1.3-10.27)]. The 
corresponding comparison of MC1R controls with unexpectedly severe late skin radiation 
reactions (n = 18) was not significant. R160W as a part of the genotype in the patients with 
unexpectedly severe acute skin radiotherapy side effects as compared to the control group was 
also significant (p = 0.043). The discovery that SNPs of MC1R are associated with worse 
acute skin reactions could potentially contribute to a predictive assay for normal tissue 
damage from radiotherapy.  
 
The third project [12] found that patient in question was for the NBCCS genetic test.   
We postulated that they may represent a new tumour suppressor gene mutation that impacts 
on immunity as well as malignancy and development.  
 
(b)  Advances in radiation techniques are essential to maximizing the therapeutic ratio. 
These techniques [14, 18, 21] were developed in an era of three dimensional conformal 
radiotherapy (3DCRT). 3DCRT was a considerable advance in megavoltage radiotherapy. 
However, the problem of 3DCRT is that the intensity of the beam cannot be finely conformed 
to the volume needing treatment. A conceptual way of thinking of this is that 3DCRT 
radiotherapy comes in “blocks”. Unfortunately tumour volumes, as with most biological 
structures, come in curves. Planning is then all about trying to fit “the round peg into the 
square hole”. It is difficult to achieve perfect conformality of the radiation dose cloud to the 
target volume requiring radiation treatment. The projects presented here all represent 
important advances in the techniques of radiation in skin cancer using 3DCRT, the only 
modality available at the time. There are now more modern techniques available like intensity 
modulated radiotherapy technique (IMRT). 
 
One way around this 3DCRT limitation is to try to fit the modalities available to the clinical 
situation. This includes lateral thinking and also the use of different types of megavoltage 
radiation. The first type is photons. Megavoltage Photon beams are “skin sparing”. The entry 
dose, the depth of the maximum dose (Dmax) and the attenuation in tissue after the maximum 
dose point are dependent on the generating energy. This beam gradually attenuates in tissue   INT. J. BIOAUTOMATION, 2012, 16(1), 43-52 
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after the Dmax. Electrons are another megavoltage radiation modality. They have a surface 
dose and also a depth dose in tissue that both increase as the generating energy is increased. 
The energy deposition of electrons suddenly decreases at a depth that is usually one third of 
the generating energy in centimeters. Planning with these beams is usually done with the aid 
of computed tomography (CT). CT does not image the skin surface well. Special care needs to 
be taken with respect to beam characteristics when planning radiation skin cancer treatment, 
especially when matching fields. Wire and other devices are used to capture skin cancer 
characteristics onto the CT data at planning. 
 
This is a collection of 3 projects of techniques for skin cancer treatment [14, 18, 20].   
These papers arose after a team of radiation therapists visited our unit from another country. 
They were amazed at how much skin cancer was treated with definite radiotherapy in our 
country. We realized that there was a need and a duty to inform other units about our home 
grown techniques. The third paper describes a particular technique for treating a unilateral 
neck for skin cancer. This particular technique saves linear accelerator time, which is 
important in departments where there are waiting lists for treatment. Further enquires after the 
publication of the first article led to the publication of the rest. Our techniques were well 
accepted. In the papers clinical considerations were stressed. Other units did implement some 
of our techniques. We knew this because of the feedback which led to the second paper in this 
section. Most importantly, linear accelerator time was used more efficiently.  
 
Knowledge of what volume to irradiate is fundamental to successful radiotherapy in skin 
cancer. Improving the therapeutic ratio in the radiotherapy of skin includes accurate radiation 
volume delineation. When dealing with increasing tumor control, this requires knowledge of 
tumour type patterns of spread, details of interaction with other modalities eg surgery and the 
avoidance of dose limiting normal tissues. It also requires knowledge of the possibilities and 
limitations of different radiation modalities. Experience is key. This collection of techniques 
is an attempt to pass on the experience gained. They exemplify the great variety of situations 
that are found in treating skin cancers. Some are included to give salutary lessons to clinicians 
in how we need to respect these tumours which can cause morbidity and mortality [10, 13,  
19, 21].  
 
This paper [20] grew out of the need for standardization of radiotherapy axillary field 
planning and treatment in an international phase-III trial investigating the role of adjuvant 
radiotherapy following lymphadenectomy for clinically apparent nodal metastasis of 
melanoma in the axilla. This was becoming a problem when the quality assurance was being 
done on the first few cases. Standardization of radiotherapy axillary field planning was 
becoming a problem in our trial. I noticed that there were some cases treated in our institution 
off trial with axillary fields not consistent with the PMCC skin unit policy that had not done 
well. I decided to do a retrospective review. The paper describes the technique used at PMCC, 
the lead centre of the trial and details the outcomes in a series of patients. The trial has since 
closed and has shown a significant benefit for the addition of adjuvant radiotherapy in this 
setting. With a follow up of over 2 years, the technique had more than a 90% (10/11) regional 
control in the group of patients treated radically. Both of the radical patients who were not 
treated according to the technique had regional failure.  
 
(c)  Clinical advances can be considered from the imaging and treatment perspectives. 
Imaging advances have underpinned many advances in radiotherapy. Improving the 
therapeutic ratio in the radiotherapy of skin includes accurate staging. These studies [10, 13, 
19] concern accurate staging. Better staging has meant that patients receive the treatment that   INT. J. BIOAUTOMATION, 2012, 16(1), 43-52 
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they need; for example, patients with disseminated disease found on a PET scan may avoid a 
useless major local treatment. Treatment related projects examine the interaction of other anti-
cancer treatments like surgery and chemotherapy with radiotherapy. These interactions are 
important to know about in these days of multidisciplinary care when one treatment may have 
an effect on another, and patients are required to start sequential treatments in a timely 
manner. Three projects were about interactions of surgery and radiotherapy. The first project 
[17] found that a delay in postoperative radiotherapy for skin cancer was associated with a 
worse. The second [8] describes what can happen when radiotherapy is not offered for a 
positive perineural deep margin following resection of a large skin cancer of the back.   
The patient developed spinal cord compression from progression of disease from the positive 
deep margin some years later. His neurological deficit was reversed with radiotherapy.   
The third project [16] describes activation and rapid progression of cSCC in three Caucasians 
with long histories of sun damaged skin following administration of Rituximab. This paper 
added to the evidence of cross reactivity of this drug with the immune system.  
 
These projects emphasize the need for appropriate referral and understanding of tumour 
biology between the multidisciplinary teams. The key point of these projects is that clinicians 
need to know the relevant place of each diagnostic and therapeutic modality and cannot be 
just an isolated expert in their own subspecialty if they want to maximize the therapeutic ratio 
for skin cancer patients. 
 
Concluding comments 
Better treatments are only effective if they can be properly delivered. Quality assurance 
measures how effectively treatments are delivered. New technologies may be ineffective if 
delivered incorrectly, and a worse therapeutic ratio for the technology may be unfairly 
inferred. QA can be applied to both structure and process and related to treatment outcome  
[9, 11]. The QA of process is important, but has not been analysed as much. This is vital 
especially in the conduct of randomized trials, upon which current standard treatments are 
based. Quality assurance of process is therefore essential in treatment delivery.   
These programs are in themselves a new technology and are growing in number and 
importance especially in areas such as medical credentialing, the setting of minimum 
requirements for licensing, and the refining of the treatment process.  
 
This paper has focused on increasing the control of skin cancer. The new technologies can be 
characterized by being mainly about molecular advances, or about clinical applications. 
Others can be seen as advances in imaging or treatment. All of them are interdependent.  
A better molecular understanding of decreasing toxicity will be manifested as a better clinical 
outcome. Better imaging is judged by its better treatment result.  
 
Analyzing the impact from molecular, clinical, imaging and treatment perspectives has 
reflected the structure of the responsible medical disciplines. Studying how new technologies 
are applied to through quality assurance completes the journey from idea to safe routine 
clinical practice. The development of guidelines [15] then makes these advances available for 
new practitioners in other departments to apply them safely and in a standard and comparable 
fashion, an important consideration for collaborative ongoing multicentre research.  
 
These studies have led to clarification of the role of new technologies, and were either 
practice changing or confirming, in their time. The author had significant involvement in the 
discovery, design and implementation. All the projects attempted to enhance the therapeutic 
ratio of treatment for the benefit of patients in the present and of the future. Clinical   INT. J. BIOAUTOMATION, 2012, 16(1), 43-52 
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Perspectives include understanding the importance of timing and interaction of therapies. 
Different treatment modalities will lead to better outcomes if instituted in the correct sequence 
and scheduling. The discovery of new interactions between therapies is only possible if 
clinicians have a high index of suspicion in the clinic. These discoveries call for better 
multidisciplinary interaction [12, 22]. 
Additionally, the projects have shown that radiation is an effective treatment modality in the 
treatment of skin cancer when delivered correctly. These papers show in particular that 
radiation treatment in skin cancer has a real place. Radiation is a modality that can help 
maximize the therapeutic ratio, lends itself to translational medicine and to a personalized 
approach to decrease mortality and cost. 
 
The studies outlined here are already generating new research to aid skin cancer patients of 
the future. Whole brain radiotherapy (WBRT), after local treatment of brain metastases in 
melanoma, is controversial, and so the author has set up a trial to investigate this question 
[23]. The trial has received Australian Federal funding of one million dollars to date and has 
accrued 78 of a needed 200 patients in 3 years, the fastest accruing WBRT trial in history.  
The first interim analysis will take place one year after the randomization of the 100
th patient. 
This trial will at last provide level one evidence on how to treat in this situation. This project 
is pivotal to the future of whole brain radiation treatment in melanoma. The author initiated 
and has driven this project and will continue to do so for the benefit of skin patients in his role 
as one of two radiation oncologists at the Melanoma Institute of Australia.  
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